JCO Precision Oncology Conversations
JCO Precision Oncology Conversations features discussions with leading authors of JCO Precision Oncology articles, hosted by Dr. Abdul Rafeh Naqash. Experts engage in conversations examining groundbreaking research in precision oncology and how these advancements are redefining treatment protocols. The series also includes fellows summarizing top articles from JCO Precision Oncology.
Episodes
JCO PO Article Insights: CTCs as Biomarkers in GBM
In this episode of JCO Precision Oncology Article Insights, host Jiasen He summarizes the article, "Beyond the Brain: Circulating Tumor Cells as a Tool for Diagnosis and Monitoring," by Lessi and colleagues. LINK TO FULL TRANSCRIPT
A Decade of Data: JCO PO and the TAPUR Study
JCO PO Editor-in-Chief Emeritus Dr. James Ford and Founding PI, ASCO TAPUR Study, Dr. Richard Schilsky discuss the 10-year anniversary of the Targeted Agent and Profiling Utilization Registry (TAPUR)™ Study and its relationship with the journal. Host Dr. Rafeh Naqash and guests discuss the inception/history of the TAPUR study, its future, and advances in precision medicine over the past decade. LI
JCO PO Article Insights: Breast Neuroendocrine Carcinoma Beyond Histology
In this JCO PO Article Insights episode, host Carolyn Lineen summarizes the article, "Breast Neuroendocrine Carcinoma: Molecular Insights Beyond Histology" by Schwartz and colleagues. LINK TO FULL TRANSCRIPT
cfDNA Epigenetics for Toxicity Monitoring
JCO PO authors Dr. James Hadfield, Dr. Grace Yiqing Zhao, and Dr. Julia Elvin at AstraZeneca share insights into the JCO PO article, "Beyond Circulating Tumor DNA for Efficacy: Can We Use Cell-Free DNA to Detect and Monitor Toxicity Signals?" Host Dr. Rafeh Naqash and guests discuss emerging evidence that cfDNA methylation profiling provides sensitive, specific signals of tissue injury across mult
JCO PO Article Insights: Clinical ctDNA Testing in Advanced Pediatric Solid Tumors
In this episode of JCO PO: Article Insights, host Jiasen He summarizes the article, "Clinical Liquid Biopsy Testing for Detection of Actionable Genomic Alterations in Children and Young Adults With Advanced Solid Tumors on the GAIN Study," by Roberts and colleagues. LINK TO FULL TRANSCRIPT
ALK+ Squamous and Adenosquamous NSCLC
JCO PO author Dr. Emily Miao at Mass General Brigham Cancer Institute shares insights into the JCO PO article, "Clinicogenomic Characteristics and Treatment Outcomes of Patients With Advanced ALK-Rearranged Squamous and Adenosquamous Non–Small Cell Lung Cancers." Host Dr. Rafeh Naqash and Dr. Miao discuss the clinicogenomic characteristics and treatment outcomes of patients with ALK+ squamous and
JCO PO Article Insights: Genomics of MTAP Loss and Co-Alteration Landscape
In this JCO PO Article Insights episode, host Carolyn Lineen summarizes the article, "Genomics of MTAP Loss in >500,000 Solid Tumor Specimens Profiled Using Comprehensive Genomic Profiling Platforms" by Dean C. Pavlick and colleagues. LINK TO FULL TRANSCRIPT
Immune Checkpoint Blockade in dMMR/MSI-H Advanced UTUC
JCO PO authors Dr. Matthew Campbell and Dr. Mohammad Moussa at The University of Texas MD Anderson Cancer Center and Baylor College of Medicine, Houston, Texas, share insights into their article, "Efficacy of Immune Checkpoint Blockade in Advanced Upper Tract Urothelial Cancer With DNA Mismatch Repair Deficiency or Microsatellite Instability." Host Dr. Rafeh Naqash and Drs. Campbell and Moussa dis
JCO PO Article Insights: Dynamic Monitoring of Anti-EGFR Resistance in Metastatic Colorectal Cancer
In this JCO PO Article Insights episode, host Jordan Goldstein summarizes the article, "EXONERATE-TRaCE: A Liquid Biopsy for Tracking Response to Anti–Epidermal Growth Factor Receptor–Based Therapy in Metastatic Colorectal Cancer" byTakahashi, et al. LINK TO FULL TRANSCRIPT
Phase II Study of Seribantumab in Tumors Harboring NRG1 Fusions
JCO PO author Dr. Tejas Patil at University of Colorado Cancer Center shares insights into the JCO PO article, "CRESTONE: A Phase II Study of the Efficacy and Safety of the HER3 Monoclonal Antibody, Seribantumab, in Solid Tumors With Neuregulin-1 (NRG1) Fusions". Host Dr. Rafeh Naqash and Dr. Patil discuss the anti-tumor activity and safety data of seribantumab from the CRESTONE study (NCT04383210
JCO PO Article Insights: Circulating Cancer Genome Atlas Study 5-year Outcomes
In this JCO PO Article Insights episode, host Carolyn Lineen summarizes the article, "Prognostic Significance of Blood-Based Multicancer Detection in Circulating Tumor DNA: Five-Year Outcomes Analysis" bySwanton et al. LINK TO FULL TRANSCRIPT
JCO PO Article Insights: Analytical Validation of Tumor-Informed ctDNA Assays for MRD
In this JCO PO Article Insights episode, host Jordan Goldstein summarizes the article, "Generic Protocols for Analytical Validation of Tumor-Informed Circulating Tumor DNA Assays for Molecular Residual Disease: The Blood Profiling Atlas in Cancer's Molecular Residual Disease Analytical Validation Working Group Consensus Recommendation" by Baden et al. TRANSCRIPT Jordan Goldstein: Hello, and welcom
Oncotype DX Breast Recurrence Score® Results from Paired CNB & SE Specimens
In this JCO Precision Oncology Article Insights episode, host Dr. Carolyn Lineen summaries the article, "Concordance of Oncotype DX Breast Recurrence Score Assay Results Between Paired Core Needle Biopsy and Surgical Excision Specimens in Hormone Receptor Positive, HER2-Negative Early-Stage Breast Cancer," by Nassar et al. TRANSCRIPT Carolyn Lineen: Hello and welcome to JCO Precision Oncology A
ctDNA in Metastatic Invasive Lobular Carcinoma
JCO PO author Dr. Foldi at UPMC Hillman Cancer Center and University of Pittsburgh School of Medicine shares insights into the JCO PO article, "Personalized Circulating Tumor DNA Testing for Detection of Progression and Treatment Response Monitoring in Patients With Metastatic Invasive Lobular Carcinoma of the Breast." Host Dr. Rafeh Naqash and Dr. Foldi discuss how serial ctDNA testing in patient
JCO PO Article Insights: Circulating Tumor DNA in Germ Cell Tumors
In this JCO Precision Oncology Article Insights episode, host Dr. Jiasen He summaries the article, "Longitudinal Evaluation of Circulating Tumor DNA as a Prognostic Biomarker to Detect Molecular Residual Disease in Germ Cell Tumors," by Hassoun et al. TRANSCRIPT Jiasen He: Hello, and welcome to the JCO Precision Oncology Article Insights. I'm your host, Jiasen He, and today, we'll be discussing
FGFR2b Prevalence in Advanced GC: FORTITUDE-101 Prescreening
JCO PO author Dr. Wainberg at UCLA shares insights into the JCO PO article, "Prevalence of FGFR2b Protein Overexpression in Advanced Gastric Cancers During Prescreening for the Phase III FORTITUDE-101 Trial." Host Dr. Rafeh Naqash and Dr. Wainberg discuss how FGFR2b prevalence was similar across geographic regions and within defined patient and sample variables regardless of the level of expressio
Palbociclib in Tumors with CDKN2A Loss or Mutation
In this JCO Precision Oncology Article Insights episode, host Dr. Harold Nathan Tan summarizes "Palbociclib in Patients With Head and Neck Cancer and Other Tumors With CDKN2A Alterations: Results From the Targeted Agent and Profiling Utilization Registry Study" by Worden et al. TRANSCRIPT Harold Nathan Tan: Welcome to JCO Precision Oncology Article Insights, where we explore research that is r
FGFR3 Alteration Status and Immunotherapy in Urothelial Cancer
JCO PO author Dr. Shilpa Gupta at Cleveland Clinic Children's Hospital shares insights into her article, "Fibroblast Growth Factor Receptor 3 (FGFR3) Alteration Status and Outcomes on Immune Checkpoint Inhibitors (ICPI) in Patients with Metastatic Urothelial Carcinoma". Host Dr. Rafeh Naqash and Dr. Gupta discuss how FGFR3 combined with TMB emerged as a biomarker that may be predictive for respons
JCO PO Article Insights: Genomic Risk Classifiers in Localized Prostate Cancer
In this JCO Precision Oncology Article Insights episode, Natalie DelRocco summarizes "Genomic Risk Classifiers in Localized Prostate Cancer: Precise but Not Standardized" by Góes et al. published on September 10, 2025. TRANSCRIPT Natalie DelRocco: Hello and welcome to JCO Precision Oncology Article Insights. I'm your host, Natalie DelRocco, and today we will be discussing the editorial "Genomic Ri
DLL3 and SEZ6 Expression in Neuroendocrine Carcinomas
Authors Drs. Jessica Ross and Alissa Cooper share insights into their JCO PO article, "Clinical and Pathologic Landscapes of Delta-Like Ligand 3 and Seizure-Related Homolog Protein 6 Expression in Neuroendocrine Carcinomas" Host Dr. Rafeh Naqash and Drs. Ross and Cooper discuss the landscape of Delta-like ligand 3 (DLL3) and seizure-related homolog protein 6 (SEZ6) across NECs from eight differen
Somatic Mutations of Colorectal Cancer by Birth Cohort
In this episode of JCO PO Article Insights, host Dr. Jiasen He summarizes the article, "Somatic Mutation Profiles of Colorectal Cancer by Birth Cohort" by Gilad, et al published October 11, 2025. TRANSCRIPT Jiasen He: Hello, and welcome to the JCO Precision Oncology Article Insights. I am your host, Jiasen He, and today, we will be discussing the JCO Precision Oncology article, "Somatic Mutatio
Areas of Uncertainty in Pancreatic Cancer Surveillance
JCO PO author Dr. Bryson Katona at the University of Pennsylvania Perelman School of Medicine shares insights into his article, "Areas of Uncertainty in Pancreatic Cancer Surveillance: A Survey Across the International Pancreatic Cancer Early Detection (PRECEDE) Consortium" Host Dr. Rafeh Naqash and Dr. Katona discuss how, given differing guidelines as well as lack of detail about how PC surveilla
Lynch Syndrome Mortality in the Immunotherapy Era
JCO PO author Dr. Asaf Maoz at Dana-Farber Cancer Institute shares insights into article, "Causes of Death Among Individuals with Lynch Syndrome in the Immunotherapy Era." Host Dr. Rafeh Naqash and Dr. Maoz discuss the causes of death in individuals with LS and the evolving role of immunotherapy. TRANSCRIPT Dr. Rafeh Naqash: Hello, and welcome to JCO Precision Oncology Conversations, where we b
JCO PO Article Insights: A Retrospective Analysis to Identify ICI-Sensitive Populations
In this JCO Precision Oncology Article Insights episode, Dr. Jiasen He summarizes JCO PO article "Synthetic Lethal Co-Mutations in DNA Damage Response Pathways Predict Response to Immunotherapy in Pan-Cancer" by Hua Zhong et al. TRANSCRIPT Jiasen He: Hello and welcome to the JCO Precision Oncology Article Insights. I am your host, Jiasen He, and today we will be discussing the JCO Precision Onc
Genomic Profile of Small Cell Bladder, Lung and Urothelial Cancer
JCO PO authors Dr. Abhishek Tripathi and Dr. Salvador Jaime-Casas at City of Hope Comprehensive Cancer Center share insights into their article, "Comparative Genomic Characterization of Small Cell Carcinoma of the Bladder Compared With Urothelial Carcinoma and Small Cell Lung Carcinoma." Host Dr. Rafeh Naqash and Drs. Tripathi and Jaime-Casas discuss a novel understanding of the genomic alteratio
JCO PO Article Insights: MUC16 Directed BiTE Therapy in Epithelioid Sarcoma
In this JCO PO Article insights episode, Dr. Jiasen He summarized the JCO PO article "Mucin 16–Directed Therapy in Pediatric Sarcomas: Case Evidence of Ubamatamab Efficacy in Epithelioid Sarcoma and Its Implications for Other Sarcoma Subtypes" by Connolly et al. TRANSCRIPT Jiasen He: Hello, and welcome to JCO Precision Oncology Article Insights. I'm your host, Jiasen He, and today we'll be discuss
BRCA-Altered Uterine Sarcoma Treated with PARP Inhibitors
JCO PO author Dr. Alison M. Schram at Memorial Sloan Kettering Cancer Center shares insights into her JCO PO article, "Retrospective Analysis of BRCA-Altered Uterine Sarcoma Treated With Poly(ADP-ribose) Polymerase Inhibitors." Host Dr. Rafeh Naqash and Dr. Schram discuss relevant genomic and clinical features of patients with BRCA-altered uterine sarcoma and the efficacy of PARPis in this populat
JCO PO Article Insights: Prognostic Gene Expression Signature and MYC Expression in Osteosarcoma
In this JCO Precision Oncology Article Insights episode, Natalie DelRocco summarizes "Prognostic Value of the G2 Expression Signature and MYC Overexpression in Childhood High-Grade Osteosarcoma" by Roelof van Ewijk et al. published on May 29, 2025. TRANSCRIPT Natalie Del Rocco: Hello, and welcome to JCO Precision Oncology Article Insights. I'm your host, Natalie DelRocco, and today we will be disc
JCO PO Article Insights: Prognostic Gene Expression Signature and MYC Expression in Osteosarcoma
In this JCO Precision Oncology Article Insights episode, Natalie DelRocco summarizes "Prognostic Value of the G2 Expression Signature and MYC Overexpression in Childhood High-Grade Osteosarcoma" by Roelof van Ewijk et al. published on May 29, 2025. TRANSCRIPT Natalie Del Rocco: Hello, and welcome to JCO Precision Oncology Article Insights. I'm your host, Natalie DelRocco, and today we will be disc
JCO PO Article Insights: Real-Time Monitoring in RCC with ctDNA
In this JCO Precision Oncology Article Insights episode, Natalie DelRocco summarizes "Real-Time Monitoring in Renal Cell Carcinoma With Circulating Tumor DNA: A Step Forward, but How Far?" by Zeynep B. Zengin et al. published on February 28, 2025. TRANSCRIPT The guest on this podcast episode has no disclosures to declare. Natalie DelRocco: Hello, and welcome to JCO Precision Oncology Article I
A Position Paper on ctDNA Testing in Clinical Trials
JCO PO author Dr. Philip Philip at Henry Ford Cancer Institute and Wayne State University shares insights into his JCO PO article, "Incorporating Circulating Tumor DNA Testing Into Clinical Trials: A Position Paper by the National Cancer Institute GI Oncology Circulating Tumor DNA Working Group." Host Dr. Rafeh Naqash and Dr. Philip discuss how prospective trials are required to clarify the role o
JCO PO Article Insights: TMB and Real-World ICI Outcomes in Melanoma
In this JCO Precision Oncology Article Insights episode, Jiasen He summarizes "Predictive Impact of Tumor Mutational Burden on Real-World Outcomes of First-Line Immune Checkpoint Inhibition in Metastatic Melanoma" by Dr. Miles C. Andrews, et al. published on June 07, 2024. Transcript The guest on this podcast episode has no disclosures to declare. Jiasen He: Hello and welcome to the JCO Precisio
Effectiveness and Cost-Effectiveness of Gene Panels in Melanoma
JCO PO author Dr. Dean A. Regier at the Academy of Translational Medicine, University of British Columbia (UBC), and the School of Population and Public Health, BC Cancer Research Institute shares insights into his JCO PO article, "Clinical Effectiveness and Cost-Effectiveness of Multigene Panel Sequencing in Advanced Melanoma: A Population-Level Real-World Target Trial Emulation." Host Dr. Rafeh
JCO PO Article Insights: Exceptional Responders with Abexinostat and Pazopanib
In this JCO PO Article Insights episode, host Harold Tan summarizes Low Kynurenine Levels Among Exceptional Responders on Phase Ib Trial of the HDAC Inhibitor Abexinostat with Pazopanib by Tsang et al, published November 07, 2024. Transcript Harold Nathan Tan: Welcome to JCO Precision Oncology Article Insights, where we explore cutting-edge discoveries in the world of cancer treatment and resear
Prognostic Artificial Intelligence Scores and Outcomes in Nonmetastatic Prostate Cancer
JCO PO author Dr. Timothy Showalter at Artera and University of Virginia shares insights into his JCO PO article, "Digital Pathology–Based Multimodal Artificial Intelligence Scores and Outcomes in a Randomized Phase III Trial in Men With Nonmetastatic Castration-Resistant Prostate Cancer" . Host Dr. Rafeh Naqash and Dr. Showalter discuss how multimodal AI as a prognostic marker in nonmetastatic ca
JCO PO Article Insights: Prognostic Artificial Intelligence Nonmetastatic Prostate Cancer
In this JCO Precision Oncology Article Insights episode, Natalie DelRocco summarizes "Digital Pathology–Based Multimodal Artificial Intelligence Scores and Outcomes in a Randomized Phase III Trial in Men With Nonmetastatic Castration-Resistant Prostate Cancer" by Felix Y. Feng, et al published January 31, 2025. Come back for the next episode where JCO Precision Oncology Conversations host, Dr. Ra
JCO PO Article Insights: Therapy of Infantile Midline Low-Grade Gliomas
In this JCO Precision Oncology Article Insights episode, Jiasen He summarizes "Midline Low-Grade Gliomas of Early Childhood: Focus on Targeted Therapies." by Dr. Ludmila Papusha et al. published on July 08, 2024. TRANSCRIPT Jiasen He: Hello and welcome to JCO Precision Oncology Article Insights. I'm your host Jiasen He, a JCO Journal's Editorial Fellow. Today, I will provide a summary on "Midli
Adagrasib Following Sotorasib-Related Hepatotoxicity
JCO PO author Dr. Hatim Husain at University of California San Diego, shares insights into his JCO PO article, "Adagrasib Treatment After Sotorasib-Related Hepatotoxicity in Patients With KRASG12C-Mutated Non–Small Cell Lung Cancer: A Case Series and Literature Review", one of the top downloaded articles of 2024. Host Dr. Rafeh Naqash and Dr. Husain discuss how to utilize real-world and clinical t
JCO PO Article Insights: ctDNA as a Prognostic Biomarker in EGC
In this JCO PO Article Insights episode, Harold Nathan Tan summarizes findings from the JCO PO article, "Circulating Tumor DNA as a Prognostic Biomarker for Recurrence in Patients With Locoregional Esophagogastric Cancers With a Pathologic Complete Response." TRANSCRIPT Harold Nathan Tan: Welcome to JCO Precision Oncology Article Insights where we explore cutting-edge discoveries in the world o
Proteomics Predictor for Immunotherapy Benefit
JCO PO author Dr. David R. Gandara at UC Davis Comprehensive Cancer Center, shares insights into his JCO PO article, "Plasma Proteome–Based Test for First-Line Treatment Selection in Metastatic Non–Small Cell Lung Cancer," one of the Top Articles of 2024. Host Dr. Rafeh Naqash and Dr. Gandara discuss how the PROphet® blood test supports first-line immunotherapy treatment decisions for metastatic N
Transcriptome and ctDNA Associates with Pembrolizumab Benefit
JCO PO authors Dr. Philippe Bedard (Staff Medical Oncologist at Princess Margaret Cancer Centre and Professor of Medicine at University of Toronto) and Dr. Alberto Hernando Calvo (Medical Oncologist at Vall d´Hebron University Hospital) share insights into their JCO PO article, "Combined Transcriptome and Circulating Tumor DNA Longitudinal Biomarker Analysis Associates With Clinical Outcomes in Ad
JCO PO Article Insights: Germline Pathogenic Variants in Renal Cell Carcinoma
In this JCO Precision Oncology Article Insights episode, Miki Horiguchi summarizes two articles: "Germline Susceptibility to Renal Cell Carcinoma and Implications for Genetic Screening," by Dr. Kate I. Glennon et al. published on August 01, 2024, and "Incidental Pathogenic Variants in Renal Cell and Urothelial Carcinoma: Is It Time for Universal Screening?" by Dr. Salvador Jaime-Casas, et al. publ
Uptake of Aspirin Chemoprevention in Lynch Syndrome
JCO PO author Dr. Michael J. Hall, Professor of Medicine, Chairman of the Department of Clinical Genetics, and Co-Leader of the Cancer Prevention and Control Program at Fox Chase Cancer Center in Philadelphia, PA, shares insights into the JCO PO article, "Uptake of Aspirin Chemoprevention in Patients with Lynch Syndrome." Host Dr. Rafeh Naqash and Dr. Hall discuss the finding that only about 1 in
JCO PO Article Insights: Talazoparib in Solid Tumors with BRCA1/2 Mutation
In this JCO Precision Oncology Article Insights episode, Mitchell Elliot summarizes the article "Talazoparib in Patients With Solid Tumors With BRCA1/2 Mutation: Results From the Targeted Agent and Profiling Utilization Registry Study" by Dr. Jordan Srkalovic et al. published on June 12th, 2024. TRANSCRIPT Mitchell Elliott: Hello, welcome to JCO Precision Oncology Article Insights. I'm your hos
Transcriptomic Profiling of Non-Localized Prostate Cancer
JCO PO author Dr. Amar U. Kishan, Professor, Executive Vice Chair, and Chief of Genitourinary Oncology Service in the Department of Radiation Oncology at the University of California, Los Angeles, shares insights into his JCO PO article, "Transcriptomic Profiling of Primary Prostate Cancers and Nonlocalized Disease on Prostate-Specific Membrane Antigen Positron Emission Tomography/Computed Tomogra
JCO PO Article Insights: MCED Test Preferentially Detects High-Grade Prostate Cancers
In this JCO Precision Oncology Article Insights episode, Mitchell Elliot summarizes an editorial: "A Targeted Methylation–Based Multicancer Early Detection Blood Test Preferentially Detects High-Grade Prostate Cancer While Minimizing Overdiagnosis of Indolent Disease" by Dr. Brandon A. Mahal, et al. published on August 29, 2024. TRANSCRIPT Mitchell Elliott: Hello and welcome to JCO Precision On
Molecular Characteristics of Early-Onset Biliary Tract Cancer
JCO PO author Dr. Alok A. Khorana, MD, FASCO, Professor of Medicine, Cleveland Clinic and Case Comprehensive Cancer Center, shares insights into the JCO PO article, "Molecular Differences With Therapeutic Implications in Early-Onset Compared With Average-Onset Biliary Tract Cancers." Host Dr. Rafeh Naqash and Dr. Khorana discuss how multiomic analysis shows higher FGFR2 fusions and immunotherapy m
JCO PO Article Insights: Publication Trends in JCO Precision Oncology
In this JCO Precision Oncology Article Insights episode, Miki Horiguchi summarizes an editorial: "Expanding the Reach of Personalized Medicine in Cancer Care: Current Progress and Future Directions of JCO Precision Oncology" by Dr. Yushu Shi et al. published on May 30, 2024. TRANSCRIPT Hello and welcome to JCO Precision Oncology Article Insights. I'm your host Miki Horiguchi, an ASCO Journals Edit
CCR Score to Predict ADT Benefit in Men with Prostate Cancer
JCO PO author Dr. Jonathan D. Tward, M.D., Ph.D., FASTRO, at the HCI Genitourinary Cancers Center and the Huntsman Cancer Institute at the University of Utah, shares insights into his JCO PO article, "Using the Cell-Cycle Risk Score to Predict the Benefit of Androgen-Deprivation Therapy Added to Radiation Therapy in Patients With Newly Diagnosed Prostate Cancer." Host Dr. Rafeh Naqash and Dr. Twar
JCO PO Article Insights: Statistical Considerations for Biomarker-Driven Oncology Clinical Trials
In this JCO Precision Oncology Article Insights episode, Miki Horiguchi summarizes two articles: "Biomarker-Driven Oncology Trial Design and Subgroup Characterization: Challenges and Potential Solutions" by Wang, et al. published on June 7, 2024, and "Biomarkers in Oncology: Complexities in Biomarker-Driven Studies and Statistical Analysis" by Uno, et al. published on July 22, 2024. TRANSCRIPT M
JCO PO Article Insights: Role of ctDNA in Appendiceal Cancer
In this JCO Precision Oncology Article Insights episode, Fergus Keane provides a summary on "Multi-Institutional Study Evaluating the Role of Circulating Tumor DNA in the Management of Appendiceal Cancers" by Belmont, et al published on May 9th, 2024. TRANSCRIPT Fergus Keane: Hello and welcome to JCO Precision Oncology Article Insights. I'm your host, Fergus Keane, an ASCO editorial fellow. Tod
PD-L1 Assay Concordance in Gastric Cancer
JCO PO author Dr. Samuel J. Klempner shares insights into his JCO PO article, "PD-L1 Immunohistochemistry in Gastric Cancer: Comparison of Combined Positive Score and Tumor Area Positivity across 28-8, 22C3, and SP263 assays". Host Dr. Rafeh Naqash and Dr. Klempner discuss assessing the analytical comparability of three commercially available PD-L1 assays and two scoring algorithms used to assess
JCO PO Article Insights: Serial Post Operative ctDNA Predicts Poor Breast Cancer Outcome
In this JCO Precision Oncology Article Insights episode, Mitchell Elliot provides a summary on "Serial Postoperative Circulating Tumor DNA Assessment Has Strong Prognostic Value During Long-Term Follow-Up in Patients With Breast Cancer" by Shaw, et al published on May 1st, 2024. TRANSCRIPT The guest on this podcast episode has no disclosures to declare. Mitchell Elliott: Hello and welcome to
Phase II Study of Erdafitinib in Tumors with FGFR Amplifications and Mutations or Fusions
JCO PO author Dr. Jun Gong shares insights into his JCO PO articles, "Phase II Study of Erdafitinib in Patients with Tumors with FGFR Amplifications: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Sub-protocol K1" and "Phase II Study of Erdafitinib in Patients with Tumors with FGFR Mutations or Fusions: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Sub-protocol K2". Host Dr. Rafeh Na
JCO PO Article Insights: Web-Based Pretest Genetic Education for Prostate Cancer Germline Testing
In this JCO PO Article Insights episode, Miki Horiguchi provides a summary on the article, "TARGET: A Randomized, Noninferiority Trial of a Pretest, Patient-Driven Genetic Education Webtool Versus Genetic Counseling for Prostate Cancer Germline Testing and explains what a non-inferiority trial is. TRANSCRIPT Miki Horiguchi: Hello and welcome to JCO Precision Oncology Article Insights. I'm your ho
Liquid Biopsy of Lung Cancer Before Pathological Diagnosis Is Associated With Shorter Time to Treatment
JCO PO author Dr. Christian Rolfo shares insights into his JCO PO article, "Liquid Biopsy of Lung Cancer Before Pathological Diagnosis Is Associated With Shorter Time to Treatment." Host Dr. Rafeh Naqash and Dr. Rolfo discuss how early liquid biopsy in aNSCLC in parallel with path dx is associated with shorter time to treatment. TRANSCRIPT Dr. Rafeh Naqash: Hello and welcome to JCO Precision
JCO PO Article Insights: Microsatellite Instability as a Biomarker in Clinical Practice
In this JCO PO Article Insights episode, Fergus Keane provides a summary on "Microsatellite Instability Is Insufficiently Used as a Biomarker for Lynch Syndrome Testing in Clinical Practice", by Papadopoulou, et al published January 25, 2024 TRANSCRIPT The guest on this podcast episode has no disclosures to declare. Fergus Keane: Hello and welcome to JCO Precision Oncology Article Insights. I'
Recommendations for the Equitable and Widespread Implementation of Liquid Biopsy
JCO PO authors Lauren C. Leiman and Dr. Emma Alme share insights into their JCO PO article, "Recommendations for the Equitable and Widespread Implementation of Liquid Biopsy for Cancer Care". Host Dr. Rafeh Naqash and guests discusses increasing access to liquid biopsy for cancer, reviewing the barriers and examining the proposed solutions. TRANSCRIPT Dr. Rafeh Naqash: Hello and welcome to JCO
JCO PO Article Insights: Prediction of Adjuvant Pertuzumab Benefit by 80-GS
In this JCO Precision Oncology Article Insights episode, Mitchell Elliot provides a summary on "Prediction of Benefit From Adjuvant Pertuzumab by 80-Gene Signature in the APHINITY (BIG 4-11) Trial," by Krop, et al published on January 18th, 2024. TRANSCRIPT Mitchell Elliott: Hello and welcome to JCO Precision Oncology Article Insights. I'm your host, Mitchell Elliott, an ASCO Journal Editorial F
MultiCancer Detection Test Performance in Symptomatic Individuals
JCO PO author Dr. Eric Klein shares insights into his JCO PO article, "Performance of a Cell-Free DNA-Based Multi-Cancer Detection Test in Individuals Presenting with Symptoms Suspicious for Cancers" Host Dr. Rafeh Naqash and Dr. Klein discuss how a multi-cancer detection test may facilitate workup and stratification of cancer risk in symptomatic individuals. TRANSCRIPT Dr. Rafeh Naqash: Hello a
JCO PO Article Insights: Diverse Study Samples in Clinical Trials
In this JCO Precision Oncology Article Insights episode, Miki Horiguchi provides a summary on "Clinical Trial Diversity: A Bend in the Arc Towards Justice", by Tannenbaum, et al published on September 19, 2023 in JCO Precision Oncology. The editorial discusses the need for inclusion of under-represented groups in clinical trials. See the accompanying Original Report, "Representativeness of Patient
Tumor Mutational Burden and Advanced Pancreatic Cancer
JCO PO author Dr. Amit Mahipal shares insights into his JCO PO article, "Tumor Mutational Burden in Real-world Patients with Pancreatic Cancer: Genomic Alterations and Predictive Value for Immune Checkpoint Inhibitor Effectiveness." Host Dr. Rafeh Naqash and Dr Mahipal discuss real world evidence of immune checkpoint inhibitors in pancreatic ductal adenocarcinoma. TRANSCRIPT Dr. Rafeh Naqash: We
Representativeness of Lung-MAP Participants
JCO PO author Dr. Mary Redman shares insights into her JCO PO article, "Representativeness of Patients Enrolled in the Lung Cancer Master Protocol (Lung-MAP)" Host Dr. Rafeh Naqash and Dr. Redman discuss the background of LungMAP and how it was developed to accelerate drug development and biomarker-driven therapies in lung cancer. Dr. Redman shares the initiatives undertaken to increase participa
Perspectives on Universal Germline Testing for Colorectal Cancer
JCO PO author Dr. Sanjeevani Arora shares insights into her JCO PO article, "Exploring Stakeholders' Perspectives on Implementing Universal Germline Testing for Colorectal Cancer: Findings from a Clinical Practice Survey" Host Dr. Rafeh Naqash and Dr. Arora discuss germline genetic testing for all colorectal cancer (CRC) patients and advantages and barriers of implementing universal germline testi
Outcomes of the IMMray PanCan-d Test in High-Risk Individuals
JCO PO author Dr. Bryson Katona shares insights into his JCO PO article, "Outcomes of the IMMray PanCan-dTM test in High-Risk Individuals Undergoing Pancreatic Surveillance: Pragmatic Data and Lessons Learned." Host Dr. Rafeh Naqash and Dr. Katona discuss IMMray PanCan-d: A Blood-based Test for Early Detection of Pancreatic Cancer. TRANSCRIPT Dr. Rafeh Naqash: Hello and welcome to JCO Precision
Implementation of the Maine Cancer Genomics Initiative
JCO PO author Dr. Jens Rueter Chief Medical Officer at The Jackson Laboratory and Medical Director of the Maine Cancer Genomics Initiative, shares insights into his JCO PO article, "The Maine Cancer Genomics Initiative: Implementing a Community Cancer Genomics Program Across an Entire Rural State." Host Dr. Rafeh Naqash and Dr. Rueter discuss this successful initiative for patients and its imple
Pertuzumab + Trastuzumab in Lung Cancer with ERBB2 Alterations
JCO PO author Dr. Apar K. Ganti shares insights into his JCO PO article, "Pertuzumab Plus Trastuzumab in Patients With Lung Cancer With ERBB2 Mutation or Amplification: Results From the Targeted Agent and Profiling Utilization Registry Study." Host Dr. Rafeh Naqash and Dr. Ganti discuss clinical decision-making regarding biopsy; HER2 amplification, mutation, and targeted therapy; drug combinations
MMR-P Colorectal Cancer in Lynch Syndrome
JCO PO author Dr. Alicia Latham shares insights into her JCO PO article, "Prevalence and Clinical Implications of Mismatch Repair-Proficient Colorectal Cancer in Patients With Lynch Syndrome." Host Dr. Rafeh Naqash and Dr. Latham discuss microsatellite instability-high status as well as familial risk and testing. Click here to read the article! TRANSCRIPT Dr. Rafeh Naqash: Hello, and welcome to J
Real-World NTRK Fusions and TRK Inhibitors in Veterans
JCO PO authors Dr. Michael J. Kelley and Dr. Katherine I. Zhou share insights into their JCO PO article, "Real-world Experience With Neurotrophic Tyrosine Receptor Kinase Fusion–positive Tumors and Tropomyosin Receptor Kinase Inhibitors in Veterans." Host Dr. Rafeh Naqash, Dr. Kelley, and Dr. Zhou discuss the robust Veterans Affairs (VA) National Precision Oncology Program (NPOP), accurate identif
Larotrectinib for TRK Fusion - Positive Lung Cancer
JCO PO author Alexander E. Drilon, MD, shares insights into his article, "Efficacy and Safety of Larotrectinib in Patients With Tropomyosin Receptor Kinase Fusion–Positive Lung Cancers" and the article's findings of the activity of larotrectinib in patients with advanced lung cancer harboring NTRK gene fusions. Host Dr. Rafeh Naqash and Dr. Drilon discuss drug development, testing for fusions, res
ctDNA for Recurrence Prediction in Esophagogastric Cancers
JCO PO author Dr. Brandon Huffman shares insights into his JCO PO article, "Analysis of Circulating Tumor DNA to Predict Risk of Recurrence in Patients With Esophageal and Gastric Cancers" and discusses the article's findings of ctDNA levels in the preoperative, postoperative, and surveillance settings in patients with EGC. Host Dr. Rafeh Naqash and Dr. Huffman discuss ctDNA assessments, treatment
KRAS Variants, G12C, TMB, high PD-L1 Expression in Solid Tumors
JCO PO author Dr. Mohamed Salem shares insights into his JCO PO article, "Landscape of KRASG12C, Associated Genomic Alterations, and Interrelation With Immuno-Oncology Biomarkers in KRAS-Mutated Cancers" and the article's findings of a large-scale, pan-cancer genomic characterization of KRASG12C. Host Dr. Rafeh Naqash and Dr. Salem discuss KRASG12C mutation, KRASG12C -mutated tumors and comutation
Universal Genetic Germline Testing in Solid Tumor Cancer Patients
JCO PO authors Dr. Edward Esplin and Professor Heather Hampel share insights into their JCO PO commentary, "Universal Germline Genetic Testing for Hereditary Cancer Syndromes in Patients With Solid Tumor Cancer" and discuss practical implications of testing for patients, geneticists, and clinicians. Host Dr. Rafeh Naqash, Dr. Esplin, and Professor Hampel discuss standard of care guidelines, insura
Tumor Mutational Burden as a Predictor of First-Line Immune Checkpoint Inhibitor Versus Carboplatin Benefit in Cisplatin-Unfit Patients With Urothelial Carcinoma, with Dr. Shilpa Gupta
JCO PO author Dr. Shilpa Gupta, MD, Associate Professor of Medicine at the Cleveland Clinic and GU Medical Oncology Director, shares analysis on outcomes in real-world settings for metastatic urothelial carcinoma (mUC) patients. Host Dr. Rafeh Naqash and Dr. Gupta discuss the utility of tumor mutational burden (TMB) to determine treatment, and mUC patient response from immune checkpoint inhibitors
Changes in Circulating Tumor DNA Reflect Clinical Benefit Across Multiple Studies of Patients With Non–Small-Cell Lung Cancer Treated With Immune Checkpoint Inhibitors, with Dr. Mark Stewart
JCO PO author Dr. Mark Stewart, PhD, Vice President, Science Policy at Friends of Cancer Research, shares analysis on clinical trials and the association between CT-DNA and outcomes in lung cancer. Host Dr. Rafeh Naqash and Dr. Stewart discuss dataset metrics, identification of biomarkers, timepoints, and checkpoint inhibitors, development of new medicines, and novel technologies measuring CT-DNA.
Clinical, Genomic, and Transcriptomic Data Profiling of Biliary Tract Cancer Reveals Subtype-Specific Immune Signatures with Dr. Mark Yarchoan
JCO PO author Dr. Mark Yarchoan, MD, of Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, shares research on the four distinct subsets of biliary tract cancers (BTCs) and their varying immune responses and mutations. Dr. Naqash and Dr. Yarchoan discuss the article's study of intrahepatic cholangiocarcinoma [IHC], extrahepatic cholangiocarcinoma, and gallbladder cancer. Click here to read th
Hyperthermic Intraperitoneal Chemotherapy–Induced Molecular Changes in Humans Validate Preclinical Data in Ovarian Cancer with Dr. Thanh Dellinger
In this JCO Precision Oncology Conversations podcast, JCO PO author Dr. Thanh Dellinger of City of Hope National Medical Center shares insights into the research published in her article, "Hyperthermic Intraperitoneal Chemotherapy–Induced Molecular Changes in Humans Validate Preclinical Data in Ovarian Cancer." Podcast host Dr. Abdul Rafeh Naqash talks with Dr. Dellinger about hyperthermic intrape
Introducing JCO Precision Oncology and Its Editor in Chief, Dr. James Ford
In this introductory episode of the JCO Precision Oncology Conversations podcast, host Dr. Abdul Rafeh Naqash, MD, from the University of Oklahoma Stephenson Cancer Center, speaks with JCO Precision Oncology's founding Editor in Chief, Dr. James Ford, MD, of Stanford University. Dr. Naqash and Dr. Ford discuss how JCO Precision Oncology (JCO PO) started as a journal and how it has progressed since
Recommended
The Church of What's Happening Now: The New Testament
Busted Open
Deadline: White House
Crickets Corner
History of the Earthquake and Fire in San Francisco
Fox news
K-Drama Obsessed Mamas | Beyond “Just One More Episode!”
True Crime Classics
The Healer Revolution
Becoming: HER with Nikki Spoelstra
Booked, Blonde & Busy w/ Olivia Ponton
McKinsey on Consumer and Retail
